Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q1 FY2025 Earnings Presentation
15 slides from Gland Pharma's earnings presentation, Aug 6, 2024
Slide 1: Gland Pharma Limited Financial Results Q1'FY25
GLAND PHARMA LIMITED Gland Pharma Limited Financial Results Q1’FY25 6th August 2024 Cemcitibii lajectiM ■
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Group Financial Highlights (1/4)
Group Financial Highlights (1/4) Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (INR Mn) (INR Mn / %) 9,381 8,375 15,375 7,558 61% 14,017 60% 12,087 63% Q1 FY24 Q1 FY25 Q4 FY24 Q1 FY24 Q1 FY25 Q4 FY24 EBITDA (3) / EBITDA Margin (4) PAT / PAT Margin (5) (INR Mn / %) (INR Mn / %) -
Slide 4: Gland Financial Highlights (Ex-Cenexi) (2/4)
Gland Financial Highlights (Ex-Cenexi) (2/4) Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn / %) (INR Mn) 11,737 4,306 10,134 37% 8,873 2,941 2,636 30% 29% Q1 FY24 Q1 FY25 Q4 FY24 Q1 FY24 Q1 FY25 Q4 FY24 PBT / PAT / PAT Margin (3) R&D Expenses (INR Mn / %) (INR Mn ) 7% 489 457 437 4,
Slide 5: Group Financial Highlights (3/4)
Group Financial Highlights (3/4) Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 87,238 88,576 30,488 27,430 24,953 21,756 Mar'24 Jun'24 Mar'24 Jun'24 Total Cash Net Cash Net Working Capital (3) Capital Expenditure ■ (INR Mn) (INR Mn) 24,074 687 637 20,129 Mar'24 Jun'24 Q1 FY24
Slide 6: Group Financial Highlights (4/4)
Group Financial Highlights (4/4) Asset Turnover Ratio (1)(2) ROCE (3) / RONW (4) (%) 1.9 1.5 1.5 10% 9% 10% 6% 0.6 9% 0.5 0.5 7% Total asset turnover Fixed asset turnover Q1 FY24 FY24 Q1 FY25 Q1 FY24 FY24 Q1 FY25 RoCE RoNW Cash Flow from Operations Cash Conversion Cycle (CCC) (5)(6) (INR Mn) (# of D
Slide 7: P&L Highlights
P&L Highlights Group P&L INR Mn Particulars Q1 FY25 Q1 FY24 YoY Q4 FY24 QoQ Revenue from operations 14,017 12,087 16% 15,375 (9%) Other Income 514 375 37% 421 22% Total Income 14,531 12,462 17% 15,796 (8%) Gross Margin(1) 8,375 7,558 11% 9,381 (11%) % margin 60% 63% 61% (2) EBITDA 2,654 2,982 (11%)
Slide 8: Base Business (Ex-Cenexi) Performance
Base Business (Ex-Cenexi) Performance Q1FY25 Highlights • Revenue: INR 10,134 million, driven by volume growth in key injectables and new product launches compared to Q1FY24. • Gross margin: 53%. • EBITDA: INR 2,941 million, EBITDA margins were at 29%, compared to 30% in Q1 FY24. • R&D expenses: INR
Slide 9: Cenexi Performance
Cenexi Performance Q1FY25 Highlights • Revenue: INR 3,883 million / Euro 43 million • Gross margin: 78% • EBITDA: INR -286 million / Euro -3 million Key Updates: Fontenay Site (Paris, France): • It is a significant revenue contributor and is showing improved operational performance due to efficiency
Slide 10: Segment wise revenue break-up
Segment wise revenue break-up IGLAND]
Slide 11: US Market
US Market Group Revenue Contribution US Market (Ex-Cenexi) ▪ Revenue: Q1 FY25: Rs. 7,628 Mn >o YoY Change: 27% Launched 8 molecules in the market, including Eribulin mesylate, Plerixafor, Nelarabine and Edaravone. Q1 Q1 ▪ New launches(1): FY24 50% FY25 54% Q1 FY25 : 11 Product SKUs (8 Molecules) ▪ U
Slide 12: Europe, Other Core Markets (Canada, Australia and New Zealand)
Europe, Other Core Markets (Canada, Australia and New Zealand) Europe Other Core Markets (Canada, Australia and New Zealand) Group Revenue Contribution Group Revenue Contribution Q1 FY25: Rs. 2,566 Mn Q1 FY25: Rs. 447 Mn YoY Change: 15% YoY Change: 72% 18% 18% 2% 3% Q1 Q1 Q1 Q1 FY24 FY25 FY24 FY25 G
Slide 13: Rest of the World Markets
Rest of the World Markets Group Revenue Contribution Rest of the World Markets (Ex-Cenexi) ▪ The Rest of the World markets contributed 15% of our Q1 FY25: Rs. 2,849 Mn YoY Change: -3% revenue in Q1 FY25, compared to 18% in Q1 FY24. 24% 20% ▪ We registered Ertapenem, Dexrazoxane, and Q1 Q1 FY24 FY25
Slide 14: India (Domestic Market)
India (Domestic Market) Group Revenue Contribution India - Domestic Market (Ex-Cenexi) Q1 FY25: Rs. 527 Mn oo ▪ The Indian market made up 5% of our revenue in Q1 YoY Change: -19% 5% 4% FY25, experiencing a 19% decrease compared to Q1 FY24. Q1 Q1 FY25 FY24 ▪ We are currently evaluating various strate
Slide 15: Gland Pharma contact details
GLAND Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District